Loading
Life sciences · Journal article
Journal of Health Sciences and Clinical Technology · October 29, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
VHL gene is a typical gene that is frequently mutated in clear cell renal cell carcinoma (ccRCC). It can promote the expression of glucose transporter 1 (GLUT1) and the Warburg effect by stabilizing hypoxia-inducible factor 1α (HIF-1α) to induce glycolytic dependence in tumour cells. Targeted Therapy to address the metabolic weakness can also be used. Systematically review the metabolic regulatory mechanism of HIF-1α/GLUT1 in VHL-inactivation and summarize the anti-tumour effects and potential applications of the selective GLUT1 inhibitor STF-31. Studies have shown that VHL dysfunction leads to the continuous accumulation of HIF-1α, which upregulates GLUT1 and glycolysis-related genes, thus promoting a state of persistent aerobic glycolysis in ccRCC cells. High expression of GLUT1 is associated with enhanced tumour invasion and a poor prognosis. STF-31 can selectively inhibit GLUT1-mediated glucose uptake to cause energy metabolism disorders, and it preferentially inhibits VHL-deficient tumour cells via synthetic lethality. Previous in vitro and animal studies have also shown that STF-31 is good at inhibiting cancer and is relatively non-toxic to normal cells. The metabolic axis of VHL-HIF-1α-GLUT1 is a potential therapeutic target for ccRCC, and STF-31 has proposed a new research direction in metabolic-targeted therapy of VHL-deficient tumours. In the future, research will be conducted to further optimise the pharmacokinetics and drug-delivery properties of STF-31, explore combination strategies with immunotherapy and anti-angiogenic therapy, and carry out clinical trials to evaluate its efficacy and safety in patients before use in patients.